www.ijarp.com ISSN 2456-9992 Page: 01-08
International Journal Advanced Research Publications
Review Article
Volume: 02
Issue: 05

# TUBERCULOSIS: A COMPREHENSIVE REVIEW OF PATHOGENESIS DIAGNOSIS AND TREATMENT

**Ovais Ashraf *, Mr Madhukar Prabhash, Ms. Tanya Sharma and Jan Mohammad**

Faculty of Pharmaceutical Sciences, Mewar University, Chittorgarh, Rajasthan-312901.

**Article Received: 24 March 2026, Article Revised: 14 April 2026, Published on: 04 May 2026**

***Corresponding Author: Ovais Ashraf**
Faculty of Pharmaceutical Sciences, Mewar University, Chittorgarh, Rajasthan-312901.
DOI: https://doi-doi.org/101555/ijarp.3785

## ABSTRACT

Millions of people die each year from tuberculosis (TB), one of the worst infectious diseases. We provide a broad overview of tuberculosis (TB) in this paper, covering its pathogenesis, diagnosis, and recommended course of therapy. We looked through PubMed for pertinent TB publications in order to prepare this article. We also looked for relevant publications and clinical guidelines on the websites of global organizations including the US Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO). The purpose of this article is to provide general information to patients, policy makers, health professionals, and the general public. Mycobacterium tuberculosis is the causative agent of tuberculosis (TB), an infectious disease that mainly affects the lungs but can potentially affect other organs. Due to issues including poverty, overcrowding, and restricted access to healthcare, it continues to be a significant global health concern, particularly in developing nations. When an infected individual coughs, sneezes, or speaks, airborne droplets of tuberculosis are released. Active disease is more likely to occur in people with compromised immune systems, such as those with HIV, diabetes, or malnutrition.

**KEYWORD:** Drug therapy, ethology, drug resistance, and tuberculosis. (TB)

## INTRODUCTION

Mycobacterium tuberculosis is the primary cause of tuberculosis (TB), a chronic infectious disease that mostly affects the lungs but can also affect other organs such the central nervous system, lymph nodes, and bones. When an infected person sneezes or coughs, airborne droplets are released. TB is still a serious worldwide health issue, especially in low- and middle-income nations, even though it is preventable and treatable(1).TB is one of the most

common infectious disease-related causes of death worldwide, often even outpacing HIV/AIDS. Millions of new cases are recorded each year, with a large burden in nations like India, according to the World Health Organization. The disease persists and spreads due to a number of factors, including poverty, malnutrition, overcrowding, and immunosuppression (particularly from HIV infection).Strong public health initiatives, timely diagnosis, and suitable treatment are necessary for effective TB control. Treatment outcomes are seriously threatened by the rise of drug-resistant strains, such as multidrug-resistant tuberculosis (MDR-TB). To lessen the global burden of tuberculosis, on-going research, better healthcare facilities, and awareness campaigns are crucial.(2)

**Historical Background**

There have been allusions to tuberculosis (TB) or diseases similar to it from numerous cultures throughout the world since ancient times. The language Samskritam (Sanskrit) contains the oldest mentions of tuberculosis. TB was called Yakshma (meaning wasting sickness) in the ancient Indian texts known as The Vedas. Ancient Chinese and Arabic literature123 describes a sickness similar to tuberculosis.(3) The term "consumption," which comes from the Latin word "consumer," has also been used to refer to tuberculosis in English literature. It seems that the Latin term tubercula, which means "a small lump," is where the word "tuberculosis" originated(4). The delicate balance between humans and the tubercle bacillus changed as a result of environmental changes brought about by people living in ever-larger communities over the course of centuries and millennia. To explain the spread of the epidemic and the subsequent reduction in tuberculosis, two different explanations have been put forth. (5)

**Diagnosis**

It's important to distinguish between the diagnosis of active TB and the discovery of LTBI. The current standard for diagnosing LTBI in adults is indirect methods such the interferon-gamma release assays (IGRA). These tests identify the release of interferon-gamma (IFN-γ) by T lymphocytes activated by relatively TB-specific antigens. False-positive results are typically not caused by prior bacilli Calmette-Guérin (BCG) immunization. The main purpose of IGRA is to look into people who have come into touch with an index patient who has infectious pulmonary tuberculosis. Testing for LTBI before administering medication to produce immunosuppression is another indication (see "Preventive treatment" below). IGRA are not appropriate for diagnosing TB that manifests clinically because they do not

differentiate between(6) A mix of clinical assessment, microbiological tests, and imaging methods are used to diagnose tuberculosis (TB), which is caused by Mycobacterium tuberculosis. Patients frequently exhibit symptoms that raise clinical suspicion, such as a chronic cough, fever, night sweats, weight loss, and exhaustion. However, laboratory tests are necessary for confirmed diagnosis. Because sputum smear microscopy uses Ziehl-Neelsen staining to identify acid-fast bacilli, it is still a commonly utilized initial diagnostic, especially in settings with low resources. Its sensitivity is limited, particularly in paucibacillary instances, despite being quick and affordable. Due to their high sensitivity and capacity to identify living organisms, culture techniques like growth on Lowenstein-Jensen media are regarded as the gold standard; yet, they take a lot of time.(7)The identification of tuberculosis has been greatly improved by molecular diagnostic methods. The GeneXpert MTB/RIF assay and other nucleic acid amplification tests allow for the quick diagnosis of M. tuberculosis and the discovery of rifampicin resistance in a matter of hours. Drug-resistant TB can also be identified with the help of line probe assays. Although it is not specific to tuberculosis, chest radiography is a helpful diagnostic tool for identifying lung abnormalities such infiltrates, cavities, and nodules(8)Latent TB infection is mostly detected by immunological testing, such as the tuberculin skin test (Mantoux test) and interferon-gamma release assays (IGRAs). These tests, however, are unable to differentiate between latent and active disease. Initiating appropriate treatment, limiting transmission, and lowering the overall burden of tuberculosis all depend on an early and correct diagnosis. (9)

**RISK FACTOR**

When compared to a person without any risk factors, the risk of TB illness varies by several orders of magnitude among those with LTBI (diagnosed as TST positive). This conclusion has been supported by a number of investigations. The tuberculin skin tests of 1472 participants in the placebo groups of two controlled clinical studies by Ferebee that looked at the effectiveness of treatment of LTBI among contacts of people with active TB and among patients in mental hospitals changed from negative to positive. In the first year of follow-up, 19 individuals whose tests converted experienced disease (12.9 cases per 1000 person-years), compared to 17 individuals during the next seven years. 1.6 cases per 1,000 person-years of follow-up(10).Healthcare workers (HCWs) are more likely to come into contact with tuberculosis. According to a review by Seidler et al., the overall incidence of TB illness among HCWs in high-income countries was less than 10 and 25 per 100,000 annually for both native-born HCWs and the general population The incidence and prevalence of latent

tuberculosis infection (LTBI) and illness among healthcare workers in low- and middle-income nations were compiled by Joshi and associates. The authors' analysis of 51 studies revealed that the yearly incidence of TB illness ranged from 69 to 5780 per 100,000, the annual risk of LTBI ranged from 0.5 to 14.3%, and the prevalence of LTBI among HCWs was 55% (CI = 33–79) (10)

**Clinical Features / Symptoms**

A chronic infectious disease, tuberculosis (TB) mainly affects the lungs (pulmonary TB), while it can also affect other organs (extrapulmonary TB). A persistent cough that lasts longer than two to three weeks is the most prevalent symptom. It may start out dry but eventually produce sputum and occasionally blood (haemoptysis). Patients frequently have fever, especially at night, and night sweats, which are thought to be indicative of active tuberculosis.Unintentional weight loss, exhaustion, anorexia (lack of appetite), and weakness are additional common symptoms that indicate the systemic nature of the infection. Advanced pulmonary instances may result in shortness of breath and chest pain. The symptoms of extra pulmonary tuberculosis (TB) differ according to the affected region. For instance, lymph node TB manifests as painless swelling, but spinal TB may result in back pain and deformity.The symptoms typically appear gradually, which increases the risk of transmission and delays diagnosis. Immuno compromised people, including those with HIV/AIDS, may experience unusual or more severe symptoms. For prompt diagnosis, treatment, and disease prevention, early identification of these clinical characteristics is crucial.

**Prevention and Control**

When TB incidence and death were still rising in the 1990s, the current global TB control strategy was initiated. With the goal of curing more than 85% of TB patients, the WHO developed the "Directly Observed Treatment, Short Course" (DOTS) policy, which mandates that each nation identify smear-positive TB cases and provide uniform Dothan estimated 25 million people have been healed by 7 DOTS, which has been applied in 180 countries.(15).The Global Plan has drawn a lot of criticism for its complexity, despite the fact that it requires the coalition of different groups to propose a variety of interventions that can be put into practice. Sustaining the political commitment, competing with other objectives, the threat of HIV, managing patients well to prevent drug resistance, developing human resources ability, improving diagnostic quality, and promoting operative research are some of

the hurdles. Additionally, consideration must be given to the quality of information and the adaption of field activities. A functional surveillance system, a sufficient evaluation system of control actions, and a thorough understanding of the local TB situation are all necessary for the use of the proper approach. There is a great deal of confusion regarding the indicators used to quantify tuberculosis in high-TB burden nations.The lack of clinical suspicion in the presence of comparable symptoms is another factor to take into account in a low burden scenario. From the standpoint of public health, this raises the risk of epidemic outbreaks, particularly those that impact children, as well as diagnostic delays and transmission times. The index case was found in over half (478) of the 1,000 pediatric active tuberculosis infections in Barcelona between 1987 and 2007. According to the same study, 75 of the 219 outbreaks (34%) that were documented between 2000 and 2007 involved children. Half of the pediatric TB cases during that time were represented by the 98 secondary cases under the age of 15.52.

**Treatment**

The goal of treating hypertension is to lower blood pressure in order to avoid consequences including heart disease, stroke, and renal failure. Lifestylechanges are crucial for all patients and are typically the first step in management. These include cutting back on salt, keeping a healthy weight, exercising frequently, abstaining from alcohol, and eating a balanced diet like the DASH (Dietary Approaches to Stop Hypertension) diet. Stress reduction and quitting smoking are also crucial. Lifestyle modifications alone can often dramatically reduce blood pressure, particularly in those with moderate hypertension. To evaluate progress and guarantee efficient control, regular monitoring is required. (12)When lifestyle modifications are insufficient or blood pressure is markedly high, pharmacological treatment is advised. Diuretics, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), calcium channel blockers, and beta-blockers are common groups of antihypertensive medications. While ACE inhibitors and ARBs relax blood arteries by influencing the renin-angiotensin system, diuretics aid in the removal of extra sodium and water, decreasing blood volume. Beta-blockers lower cardiac output and heart rate, while calcium channel blockers lower vascular resistance. Patient-specific variables like age, comorbidities, and the severity of hypertension influence the medication selection. To get the best blood pressure control, a combination of medications is frequently needed. For long-term management, medication adherence and routine follow-up are essential. . (13) When lifestyle modifications are insufficient or blood pressure is markedly high, pharmacological treatment is advised.

Diuretics, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), calcium channel blockers, and beta-blockers are common groups of antihypertensive medications. While ACE inhibitors and ARBs relax blood arteries by influencing the renin-angiotensin system, diuretics aid in the removal of extra sodium and water, decreasing blood volume. Beta-blockers lower cardiac output and heart rate, while calcium channel blockers lower vascular resistance. Patient-specific variables like age, comorbidities, and the severity of hypertension influence the medication selection. To get the best blood pressure control, a combination of medications is frequently needed. For long-term management, medication adherence and routine follow-up are essential.(12)

**Pathophysiology**

The infected droplets settle throughout the airways after being breathed. The goblet cells that secrete mucus are located in the higher regions of the airways, where most of the bacilli are confined. The cilia on the cell surface continuously beat the mucus and its trapped particles upward for elimination once the mucus produced captures foreign substances.8 For the majority of people exposed to tuberculosis, this mechanism offers the body a first physical resistance that keeps them from being infected(14)

The complement protein C3 attaches itself to the cell wall and improves macrophage identification of the mycobacteria. Even in the air passages of a host that has never been exposed to M TB, opsonization by C3 occurs quickly(15). The subsequent phagocytosis by macrophages initiates a cascade of events that results in either successful control of the infection, followed by latent tuberculosis, or progression to active disease, called primary progressive tuberculosis. Granuloma production is started in less immunocompetent individuals, but it ultimately fails to contain the bacilli. (16) The fibrous wall loses structural integrity and the necrotic tissue liquefies. An air-filled hollow may remain at the original location as the semiliquid necrotic material drains into a bronchus or adjacent blood artery. M TB sufferers may cough up droplets from their bronchus that spread the infection to other people. Extrapulmonary TB is likely to occur if release into a vessel takes placeAdditionally, bacilli can enter the lymphatic system and gather in the lung's tracheobronchial lymph nodes, where they can develop into fresh caseous granulomas(17)

**CONCLUSION**

Despite being a preventable and treatable disease, tuberculosis (TB) continues to be a significant global public health concern. This study emphasizes that Mycobacterium

tuberculosis is still a major source of illness and mortality, especially in low- and middle-income nations where the disease spreads due to immunosuppression, poverty, malnutrition, and overcrowding. Whether an infection develops into an active disease or stays latent depends critically on the intricate pathophysiology of tuberculosis, which includes host immune responses and granuloma development.Effective disease treatment and transmission control depend on early and accurate diagnosis using a mix of modern molecular tools, microbiological testing, and clinical evaluation. The burden of disease can also be greatly decreased by identifying high-risk groups and addressing contributory risk factors. Treatment success is seriously threatened by the advent of drug-resistant TB strains, such as multidrug-resistant TB (MDR-TB), which calls for close observation and suitable therapeutic approaches.Strong public health systems, the application of tactics like DOTS, immunization campaigns, and raised awareness are all necessary for effective prevention and management. To guarantee recovery and avoid resistance, standardized medication regimens must be used in a timely and suitable manner. Fighting tuberculosis requires ongoing research, better healthcare facilities, and international cooperation. Overall, lowering the worldwide burden of tuberculosis requires a comprehensive strategy that incorporates early diagnosis, efficient treatment, and preventive measure

**REFERENCE**


1. Agyeman AA, Ofori-Asenso R. Tuberculosis—an overview. J Public Heal Emerg. 2017;1(3):7–7.
2. Sharma SK, Mohan A. Tuberculosis: From an incurable scourge to a curable disease - Journey over a millennium. Indian J Med Res. 2013;137(3):455–93.
3. Kokiwar PR, Gupta SS, Durge PM. Prevalence of hypertension in a rural community of Central India. J Assoc Physicians India. 2012;60(6):26–9.
4. History of tuberclosis. ournal Pet Technol 26 -41. 1998;5:4.
5. Loddenkemper R, Murray JF, Gradmann C, Hopewell PC, Kato-Maeda M. History of tuberculosis. ERS Monogr. 2018;2018(9781849841009):8–27.
6. Xaubet a, Ancochea J, Blanquer R, Montero C, Morell F, Becerra ER. RECOMMENDATIONS OF THE SPANISH SOCIETY OF PULMONOLOGY Diagnosis and Treatment of Diffuse Interstitial Lung Diseases. Arch Bronchoneumol. 2003;39(12):580–600.
7. Jebai R, Osibogun O, Li W, Gautam P, Bursac Z, Ward KD, et al. Temporal Trends in Tobacco Product Use Among US Middle and High School Students: National Youth

Tobacco Survey, 2011-2020. Public Health Rep. 2023;138(3):483–92.

8. Méchaï F, Cordel H, Guglielmetti L, Aubry A, Jankovic M, Viveiros M, et al. Management of Tuberculosis: Are the Practices Homogeneous in High-Income Countries? Front Public Heal. 2020;8(September).
9. Dar IA. National health Programs . Technological Innovations under India ' s Public Health Initiatives . :1–15.
10. Burrill J, Williams CJ, Bain G, Conder G, Hine AL, Misra RR. Tuberculosis: A radiologic review. Radiographics. 2007;27(5):1255–73.
11. Lucking SE, Maffei FA, Tamburro RF. PEDIATRIC CRITICAL CARE STUDY GUIDE:TEXT AND REVIEW. 2013;308(17):2012–3.
12. Sudre P, Ten Dam G, Kochi A. Tuberculosis: A global overview of the situation today. Bull World Health Organ. 1992;70(2):149–59.
13. Dunlap NE, Briles DE. Immunology of tuberculosis. Med Clin North Am. 1993;77(6):1235–51.
14. Ramírez-Lapausa M, Menéndez-Saldaña A, Noguerado-Asensio A. Tuberculosis extrapulmonar, una revisión. Rev Esp Sanid Penit. 2015;17(1):3–11.
15. Knechel NA. Tuberculosis: Pathophysiology, clinical features, and diagnosis. Crit Care Nurse. 2009;29(2):34–43.
16. Vanino E, Granozzi B, Akkerman OW, Munoz-Torrico M, Palmieri F, Seaworth B, et al. Update of drug-resistant tuberculosis treatment guidelines: A turning point. Int J Infect Dis [Internet]. 2023;130:S12–5. Available from: https://doi.org/10.1016/j.ijid.2023.03.013
17. Velayati AA. Tuberculosis in children. Int J Mycobacteriology. 2016;5:S1–2.